Alpha 2.0
Login Register
» Authors » Yoshiaki Mori

Yoshiaki Mori

Explore the profile of Yoshiaki Mori including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 305
Followers 0
Related Specialties
Oncology
Physiology
Pharmacology
Top 10 Co-Authors
Takahiro Kubota
Akira Inoue
Hiroshi Takenaka
Taku Nakagawa
Masahito Watanabe
Shunichi Sugawara
Yasushi Goto
Yoshiro Sohma
Yukio Hosomi
Takaki Inui
Published In
J Physiol Sci
Bull Environ Contam Toxicol
J Infect Chemother
Nihon Hinyokika Gakkai Zasshi
Oncologist
Affiliations
Soon will be listed here.
Recent Articles
1.
Benign Symmetric Lipomatosis of the Tongue With Dysgeusia: A Case Report and Literature Review
Hyakusoku H, Mori Y, Yakeishi M, Kamoshida R, Nakayama M
Cureus . 2025 Feb; 17(1):e76779. PMID: 39897191
Benign symmetric lipomatosis (BSL) is a rare disorder that is characterized by diffuse growth, multiple symmetrical accumulation, and unencapsulated lipomas. BSL is also known as Madelung disease, Launois-Bensaude syndrome, and...
2.
Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in...
Tokimatsu I, Matsumoto T, Tsukada H, Fujikura Y, Miki M, Morinaga Y, et al.
J Infect Chemother . 2023 Apr; 29(8):731-743. PMID: 37116613
The trends and prevalence of antimicrobial susceptibility of pathogens vary by country, region, and time. Long-term regular surveillance is required to investigate trends in the antimicrobial resistance of various isolated...
3.
Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer
Ito T, Nagashima H, Akiyama M, Utsumi Y, Sato H, Chiba S, et al.
Thorac Cancer . 2021 Dec; 13(3):386-393. PMID: 34904383
Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have become the gold standard for EGFR-mutated non-small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the...
4.
Prospective Multicenter Study of Chemotherapy-Induced ( Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204
Toi Y, Kobayashi T, Harada T, Nakagawa T, Mori Y, Kuda T, et al.
Front Oncol . 2021 Aug; 11:685320. PMID: 34336670
Background: Diarrhea post-antibiotic use is primarily attributed to mucosal lesions induced by ( () infection (CDI). Cancer patients undergoing chemotherapy might have a higher risk of CDI even when prior...
5.
Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001
Watanabe K, Toi Y, Nakamura A, Chiba R, Akiyama M, Sakakibara-Konishi J, et al.
Transl Lung Cancer Res . 2021 Mar; 10(2):712-722. PMID: 33718016
Background: The optimal regimen for concurrent chemoradiotherapy (CCRT) of locally advanced non-squamous non-small cell lung cancer (NSCLC) was not definitive. We conducted randomized phase II study, NJLCG0601, and chemoradiotherapy with...
6.
Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of japanese society of chemotherapy, the japanese association for infectious diseases, and the japanese society for clinical microbiology in 2016:...
Yanagihara K, Matsumoto T, Tokimatsu I, Tsukada H, Fujikura Y, Miki M, et al.
J Infect Chemother . 2020 Jun; 26(9):873-881. PMID: 32565151
The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from the patients in Japan was conducted by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and...
7.
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial
Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, et al.
JAMA Oncol . 2020 May; 6(7):e201250. PMID: 32407455
Importance: Although the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for EGFR gene mutation-positive non-small cell lung cancer is well established, optimal dosing remains to be established, especially...
8.
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401
Iwama E, Goto Y, Murakami H, Tsumura S, Sakashita H, Mori Y, et al.
Oncologist . 2020 Apr; 25(4):306-e618. PMID: 32297438
Lessons Learned: Alectinib confers a pronounced survival benefit in patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status. Survival benefit of alectinib for patients with a...
9.
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study
Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, et al.
Oncologist . 2019 Nov; 25(4):e668-e674. PMID: 31771990
Background: Owing to the rarity of this tumor, there is limited information about second-line chemotherapy for patients with previously treated advanced thymic carcinoma. Material And Methods: We performed a multi-institutional,...
10.
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203
Tsukita Y, Inoue A, Sugawara S, Kuyama S, Nakagawa T, Harada D, et al.
Lung Cancer . 2019 Nov; 139:89-93. PMID: 31751805
Objectives: Invasive thymoma (IT) and thymic carcinoma (TC) are rare epithelial neoplasms arising in the anterior mediastinum. Platinum-based chemotherapies are widely used for first-line treatment of unresectable IT and TC,...